دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Expanding access to childhood and AYA cancer care
doi : 10.1016/S1470-2045(21)00416-2
Volume 22, Issue 8, August 2021, Page 1047
Alcohol and the global burden of cancer: what are we missing?
Amy CJusticea
doi : 10.1016/S1470-2045(21)00329-6
Volume 22, Issue 8, August 2021, Pages 1048-1049
Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses
JuanFueyoaCandelariaGomez-ManzanoaFrederick FLangbMarta MAlonsocde
doi : 10.1016/S1470-2045(21)00296-5
Volume 22, Issue 8, August 2021, Pages 1049-1051
HER2: a never ending story
Maria VittoriaDieciabFedericaMigliettaab
doi : 10.1016/S1470-2045(21)00349-1
Volume 22, Issue 8, August 2021, Pages 1051-1052
Who should manage post-treatment care for patients with colon cancer: surgeons or general practitioners?
EvaAngenetea
doi : 10.1016/S1470-2045(21)00379-X
Volume 22, Issue 8, August 2021, Pages 1053-1054
Improving single-agent chemoresistance risk identification in gestational trophoblastic neoplasia
GabriellaFerrandinaabGiovanniScambiaab
doi : 10.1016/S1470-2045(21)00327-2
Volume 22, Issue 8, August 2021, Pages 1054-1056
Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer
CarolineHuynhacMarkSorinabRoniRayesacPierre OFisetbdLogan AWalshabJonathan DSpicerac
doi : 10.1016/S1470-2045(21)00405-8
Volume 22, Issue 8, August 2021, Pages 1056-1058
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
MengqianLia
doi : 10.1016/S1470-2045(21)00326-0
Volume 22, Issue 8, August 2021, Page e342
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply
Ines Piresda SilvaacTasniaAhmedaIrene L MReijersdAllison BetofWarnerfJames RandallPatrinelygPatricioSerra-BellverhClaraAllayousjJoannaManganakLisaZimmerlClaudiaTrojaniellomOliverKleinoCamille LGerardpOlivierMichielinpAndrewHaydonnPaolo AAsciertomMatteo SCarlinoacCelesteLebbejPaulLoriganhiDouglas BJohnsongShahneenSandhueSerigne NLoaAlexander MMenziesabGeorgina VLongab
doi : 10.1016/S1470-2045(21)00419-8
Volume 22, Issue 8, August 2021, Pages e343-e344
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma
BinghaoZhaoabWenbinMaabcd
doi : 10.1016/S1470-2045(21)00378-8
Volume 22, Issue 8, August 2021, Page e345
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma – Authors' reply
Martin Jvan den BentaMirceaTesileanuaEORTC CATNON investigators
doi : 10.1016/S1470-2045(21)00418-6
Volume 22, Issue 8, August 2021, Page e346
Correction to Lancet Oncol 2019; 20: 1211–25
doi : 10.1016/S1470-2045(21)00413-7
Volume 22, Issue 8, August 2021, Page e347
Correction to Lancet Oncol 2021; 22: 977–90
doi : 10.1016/S1470-2045(21)00386-7
Volume 22, Issue 8, August 2021, Page e347
Correction to Lancet Oncol 2021; 22: 919–30
doi : 10.1016/S1470-2045(21)00414-9
Volume 22, Issue 8, August 2021, Page e347
Correction to Lancet Oncol 2021; 22: 959–69
doi : 10.1016/S1470-2045(21)00392-2
Volume 22, Issue 8, August 2021, Page e347
Correction to Lancet Oncol 2021; 22: 1061
doi : 10.1016/S1470-2045(21)00393-4
Volume 22, Issue 8, August 2021, Page e347
Correction to Lancet Oncol 2021; 22: 1081–92
doi : 10.1016/S1470-2045(21)00417-4
Volume 22, Issue 8, August 2021, Page e347
Getting back on track with HPV vaccination to prevent cancer
ManjulikaDas
doi : 10.1016/S1470-2045(21)00381-8
Volume 22, Issue 8, August 2021, Page 1059
COVID-19 pandemic causes cervical cancer screening crisis
ElizabethGourd
doi : 10.1016/S1470-2045(21)00382-X
Volume 22, Issue 8, August 2021, Page 1060
The challenges of cancer care for the LGBTQ+ community
Talha KhanBurki
doi : 10.1016/S1470-2045(21)00389-2
Volume 22, Issue 8, August 2021, Page 1061
ESMO World Congress on Gastrointestinal Cancer 2021
KatherineGourd
doi : 10.1016/S1470-2045(21)00395-8
Volume 22, Issue 8, August 2021, Page 1062
Lebanon faces critical shortage of drugs
ManjulikaDas
doi : 10.1016/S1470-2045(21)00396-X
Volume 22, Issue 8, August 2021, Page 1063
Serbia faces bleak cancer situation
ManjulikaDas
doi : 10.1016/S1470-2045(21)00397-1
Volume 22, Issue 8, August 2021, Page 1064
New radiation health standard required for deep space travel
ElizabethGourd
doi : 10.1016/S1470-2045(21)00398-3
Volume 22, Issue 8, August 2021, Page 1065
UK Government urged to prioritise improvements to NHS imaging services
Talha KhanBurki
doi : 10.1016/S1470-2045(21)00415-0
Volume 22, Issue 8, August 2021, Page 1066
Should stereotactic radiotherapy be the preferred treatment for oligometastatic disease?
DavidPalmaAlisonTreeMatthiasGuckenberger
doi : 10.1016/S1470-2045(21)00203-5
Volume 22, Issue 8, August 2021, Pages 1067-1068
CanStaging+: an electronic staging tool for population-based cancer registries
IsabelleSoerjomataramaMortenErvikaColinFoxbSineadHawkinsbKennethYeungbGiulioNapolitanocZuzannaTittenbrundFreddieBrayaAnnaGavinb
doi : 10.1016/S1470-2045(21)00188-1
Volume 22, Issue 8, August 2021, Page 1069
Verna Vanderpuye—special mentor for cancer care in Africa
JulesMorgan
doi : 10.1016/S1470-2045(21)00394-6
Volume 22, Issue 8, August 2021, Page 1070
Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study
HarrietRumgayBScaKevinShieldPhDcdeHadrienCharvatPhDaPietroFerrariPhDbBunditSornpaisarnPhDceProfIsidoreObotPhDgFarhadIslamiPhDhProfValery E P PLemmensPhDijProfJürgenRehmPhDcdefklIsabelleSoerjomataramPhDa
doi : 10.1016/S1470-2045(21)00279-5
Volume 22, Issue 8, August 2021, Pages 1071-1080
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
ProfXiaotianZhangMDa†ProfHanLiangMDb†ProfZiyuLiMDa†ProfYingweiXueMDc†ProfYanongWangMDeProfZhiweiZhouMDfProfJirenYuMDgProfZhaodeBuMDaProfLinChenMDlProfYianDuMDiProfXinbaoWangMDiProfAiwenWuMDaProfGuoliLiMDjProfXiangqianSuMDaProfGangXiaoMDkProfMingCuiMDaProfDanWuMDlProfLiChenMDhProfXiaojiangWuMDaProfYanbingZhouMDmProfLianhaiZhangaProfChengxueDangMDnProfYulongHeMDoProfZhongtaoZhangMDpProfYihongSunMDqProfYongLiMDrProfHuanqiuChenMDsProfYuxianBaiMDdChangsongQiMDaProfPeiwuYuMDtProfGuanbaoZhuMDuProfJianSuoMDvProfBaoqingJiaMDhProfLepingLiMDwProfChangmingHuangMDxProfFeiLiMDyProfYingjiangYeMDzProfHuimianXuMDaaProfXinWangMDabYannanYuanMSaJian-YuEMDacXiangjiYingMSaProfChenYaoMDadProfLinShenMDaProfJiafuJiMDaon behalf of theRESOLVE study group
doi : 10.1016/S1470-2045(21)00297-7
Volume 22, Issue 8, August 2021, Pages 1081-1092
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
XiaofeiZhuMDa†YangsenCaoMDa†WenyuLiuMDb†XiaopingJuMDa†XianzhiZhaoMDaLingongJiangMDaYushengYeMDaProfGangJinMDbProfHuojunZhangMDa
doi : 10.1016/S1470-2045(21)00286-2
Volume 22, Issue 8, August 2021, Pages 1093-1102
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
JawadFaresMDaAtique UAhmedPhDaIlya VUlasovPhDaAdam MSonabendMDaJasonMiskaPhDaCatalinaLee-ChangPhDaIrina VBalyasnikovaPhDaProfJames PChandlerMDaJanaPortnowMDgMatthew CTateMDaPriyaKumthekarMDbRimas VLukasMDbSean AGrimmMDbAnn KAdamsJDcCharles DHébertPhDiProfTheresa VStrongPhDjChristinaAmideiPhDaVictor AArrietaMDaMarkellaZannikouPhDaProfCraigHorbinskiMDafProfHuiZhangPhDdKirsten BellBurdettMSdProfDavid TCurielMDkSeanSachdevMDeProfKaren SAboodyMDhProfRogerStuppMDaProfMaciej SLesniakMDa
doi : 10.1016/S1470-2045(21)00245-X
Volume 22, Issue 8, August 2021, Pages 1103-1114
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
AndreiGafitaMDaJeremieCalaisMDaTristan RGroganMScbProfBorisHadaschikMDcHuiWangMSceManuelWeberMDdProfShahneenSandhuMBBSgiClemensKratochwilMDjRouzbehEsfandiariMDkRobertTauberMDfAnnaZeldinBSclHendrikRathkeMDjWesley RArmstrongBScaAndrewRobertsonMBChBePanThinBScaCalogeroD'AlessandriaPhDeProfMatthew BRettigMDmEbrahim SDelpassandMDkProfUweHaberkornMDjProfDavidElashoffPhDbProfKenHerrmannMDdProfJohannesCzerninMDaProfMichael SHofmanMBBShiWolfgang PFendlerMDdProfMatthiasEiberMDe
doi : 10.1016/S1470-2045(21)00274-6
Volume 22, Issue 8, August 2021, Pages 1115-1125
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
ProfMarcia SBroseMDaProfBruceRobinsonMDbProfSteven IShermanMDcJolantaKrajewskaMDdProfChia-ChiLinMDeFernandaVaismanMDfAna OHoffMDgErikaHitreMDhDaniel WBowlesMDiJorgeHernandoMDjLeonardoFaoroMDkKamalikaBanerjeeMSckJennifer WOliverMDkBhumsukKeamMDlJaumeCapdevilaMDj
doi : 10.1016/S1470-2045(21)00332-6
Volume 22, Issue 8, August 2021, Pages 1126-1138
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13?864 women in seven randomised trials
Early Breast Cancer Trialists’ Collaborative group (EBCTCG)†
doi : 10.1016/S1470-2045(21)00288-6
Volume 22, Issue 8, August 2021, Pages 1139-1150
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
ProfCarstenDenkertMDabFenjaSeitherMScbProfAndreasSchneeweissMDcTheresaLinkMDdProfJens-UweBlohmerMDfMarianneJustMDgProfPaulineWimbergerMDdAlmuthForbergerMDeProfHansTeschMDhProfChristianJackischMDiSabineSchmatlochMDjMatteaReinischMDkProfErich FSolomayerMDlProfWolfgang DSchmittMDmClausHanuschMDnProfPeter AFaschingMDoKristinaLübbeMDpProfChristineSolbachMDqProfJensHuoberMDqProfKerstinRhiemMDsProfFrederikMarméMDtToralfReimerMDuProfMarcusSchmidtMDvBruno VSinnMDmProfWolfgangJanniMDrProfElmarStickelerMDwLauraMichelMDcOliverSt?tzerMDxEricHahnenPhDsJennyFurlanettoMDbSabineSeilerMDbValentinaNekljudovaPhDbProfMichaelUntchMDyProfSibylleLoiblMDbz
doi : 10.1016/S1470-2045(21)00301-6
Volume 22, Issue 8, August 2021, Pages 1151-1161
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
ProfYunpengYangMDa*ProfSongQuMDb*ProfJingaoLiMDc*ProfChaosuHuPhDd*ProfMingjunXuMMe*ProfWeidongLiMSf*TingZhouMDa*ProfLiangfangShenPhDgProfHuiWuMDhProfJinyiLangMDiProfGuangyuanHuMDjProfZhanxiongLuoMSkProfZhichaoFuMDlProfShenhongQuMDmProfWeinengFengMMnProfXiaozhongChenMDoProfShaojunLinBSpProfWeiminZhangMDqProfXiaojiangLiMSrProfYanSunMDsProfZhixiongLinMDtProfQinLinMDuProfFengLeiPhDvProfJiantingLongMDwProfJinshengHongMDxProfXiaomingHuangMDyProfLingzhiZengBSzProfPeiguoWangMDaaProfXiaohuiHeMDabBenZhangMSacQingYangMDacXiaojingZhangMDacJianjunZouMDacProfWenfengFangMDa†ProfLiZhangMDa†
doi : 10.1016/S1470-2045(21)00302-8
Volume 22, Issue 8, August 2021, Pages 1162-1174
Effect of general practitioner-led versus surgeon-led colon cancer survivorship care, with or without eHealth support, on quality of life (I CARE): an interim analysis of 1-year results of a randomised, controlled trial
Julien A MVosMDacLaura A MDuineveldMDaThijsWieldraaijerPhDaJanWindPhDaWim BBusschersMScaEdanurSertMScaProfPieter JTanisPhDbdProfIrma MVerdonck-de LeeuwPhDcdeProfHenk C P Mvan WeertPhDacKristel Mvan AsseltPhDacI CARE study group†
doi : 10.1016/S1470-2045(21)00273-4
Volume 22, Issue 8, August 2021, Pages 1175-1187
Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study
AntonioBragaMDabcd*GabrielaPaivaMDab*EhsanGhoraniMDe*FernandaFreitasMDabLuis Guillermo CocaVelardePhDcBaljeetKaurFRCPatheNickUnsworthMSceJingkyLozano-KuehnePhDeAna Paula Vieirados Santos EstevesPhDaProfJorgeRezende FilhoMDabJoffreAmimJrMDabXianneAguiarBSceNaveedSarwarMDeKevin MEliasMDfNeil SHorowitzMDfProfRoss SBerkowitzMDf†ProfMichael JSecklFMedScie†
doi : 10.1016/S1470-2045(21)00262-X
Volume 22, Issue 8, August 2021, Pages 1188-1198
Elective nodal radiotherapy in prostate cancer
ProfGertDe MeerleerPhDaCharlienBerghenMDaProfAlbertoBrigantiPhDcChristofVulstekePhDeJuliaMurrayPhDfStevenJoniauPhDbAnne MLeliveldPhDgCesareCozzariniPhDdKarelDecaesteckerPhDhKatoRansMDaValerieFonteynePhDiOlivierDe HertoghMDjAlbertoBossiPhDk
doi : 10.1016/S1470-2045(21)00242-4
Volume 22, Issue 8, August 2021, Pages e348-e357
Novel therapeutic strategies: targeting epithelial–mesenchymal transition in colorectal cancer
NanZhangMMabcd†Aik SengNgBScbc†ShijieCaiMDbcProfQiuLiMDadProfLiYangMDaceProfDavidKerrMDabc
doi : 10.1016/S1470-2045(21)00343-0
Volume 22, Issue 8, August 2021, Pages e358-e368
The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research
ProfPriyaRanganathanMDaProfGirishChinnaswamyMDbProfManjuSengarDMcDurgaGadgilMDdShivakumarThiagarajanMSeProfBalramBhargavaDMgProfChristopher MBoothMDhMarcBuyseScDijSanjivChopraMDkProfChrisFramptonPhDlSatishGopalMDmNickGrantMEngnProfMarkKrailoPhDoProfRuthLangleyPhDpPrashantMathurPhDqProfXavierPaolettiPhDrstProfMaheshParmarDPhilpProfArniePurushothamMDuDouglasPyleMBAwPreethaRajaramanPhDxyProfMartin RStocklerMBBSzProfRichardSullivanPhDvSoumyaSwaminathanMDaaProfIanTannockMDabEdwardTrimbleMDacProfRajendra ABadweMSfProfC SPrameshMSfon behalf of theNational Cancer Grid of India
doi : 10.1016/S1470-2045(21)00077-2
Volume 22, Issue 8, August 2021, Pages e369-e376
Neuroendocrine tumour of the gallbladder
HarsimranBhatiaMDaAninditaSinhaMDaHarishBhujadeMDaProfKimVaipheiMDbProfVirendraSinghDMc
doi : 10.1016/S1470-2045(21)00198-4
Volume 22, Issue 8, August 2021, Page e377
